Literature DB >> 15047180

Differential regulation of IGF-II-induced IL-8 by extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinases in human keratinocytes.

Hye Jung Kim1, Sung June Byun, Tae-Yoon Kim.   

Abstract

In order to study the relationship between insulin like growth factor-II (IGF-II) and interleukin-8 (IL-8) that are upregulated in psoriasis, we monitored IL-8 expression in IGF-II-treated human keratinocytes and explored the signaling pathways of IL-8 expression by IGF-II. IGF-II increased the IL-8 mRNA and protein levels in human keratinocytes. The upregulation of IL-8 expression by IGF-II was reduced by pretreatment with inhibitors of tyrosine kinase, Src, PI3-kinase, and ERK, but not by p38. Furthermore, IGF-II remarkably increased the DNA binding activities of NF-kappaB and AP-1, and the IL-8 promoter activity. However, cotransfection with IkappaB mutant blocked the IGF-II-induced IL-8 promoter activity. In addition, cotransfection with dominant negative MEK1 mutant, but not with dominant negative p38 mutant, blocked the IGF-II-induced IL-8 promoter activity. These results suggest that IGF-II is involved in the pathogenesis of psoriasis by inducing IL-8 gene expression through the tyrosine kinase-Src-ERK1/2-AP-1 pathway, and the PI3-kinase and NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047180     DOI: 10.1016/j.bbrc.2004.03.042

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Induction of CXC chemokines in human mesenchymal stem cells by stimulation with secreted frizzled-related proteins through non-canonical Wnt signaling.

Authors:  David S Bischoff; Jian-Hua Zhu; Nalini S Makhijani; Dean T Yamaguchi
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

2.  Expression of interleukins 7 & 8 in peripheral blood mononuclear cells from patients with metabolic syndrome: a preliminary study.

Authors:  M Saidijam; A S Tootoonchi; M T Goodarzi; T Hassanzadeh; S H Borzuei; R Yadegarazari; N Shabab
Journal:  Indian J Med Res       Date:  2014-08       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.